UPDATED: CDER Agenda Foreshadows Release of Guidances Long Sought by Industry

Posted 29 July 2013 By Alexander Gaffney, RF News Editor

The Center for Drug Evaluation and Research (CDER), the US Food and Drug Administration's (FDA) primary drug regulatory body for chemical and biological drugs, has released a comprehensive list of all guidance documents it plans to release during the 2013 calendar year, including many long-awaited by the pharmaceutical and biopharmaceutical industries.

Update (8 March 2013): FDA regulators have added three new guidance documents set to be released by CDER in the coming year. The 8 March 2013 release includes Standards for Clinical Trial Imaging Endpoints, Clinical Lactation Trials - Trial Design, Data Analysis and Recommendations for Labeling and Pharmacokinetics During Pregnancy and the Postpartum Period - Trial Design, Data Analysis, and Impact on Dosing and Labeling.

Update II (29 July 2013): FDA regulators have made still more changes to the guidance list, deleting one proposed guidance while adding two others. The 29 July 2013 changes have deleted "Size and Physical Attributes of Generic Tablets" from the list, but have added "Pulmonary Tuberculosis: Developing Drugs for Treatment" and "Submission of Study Protocols for Drug Products with Certain Risk Evaluation and Mitigation Strategies for Review by the Office of Generic Drugs."

The 59 proposed guidance documents-new and revised documents in both final and draft form-fall into 17 distinct categories spanning clinical, advertising, safety, chemistry, bioequivalence and niche issues such as use of the animal rule.

One of the most notable guidance documents set to be released is one on biosimilarity (#4), which will reportedly detail the recommended submission format for pharmacology data used as evidence of biosimilarity. Another guidance (#50), will detail the expected process for formal meetings held between FDA and sponsors of 351(k) submissions.

Another notable document will include track and trace provisions for drug packaging (#34), provisions long called for by many in the industry but stalled over questions regarding its specifics. This provision would, it seems, apply only to the packaging of products, leaving open the question of whether the agency believes a lot-level or unit-level traceability level is preferable.

Two other guidance areas of importance include the use of electronic formats for regulatory submissions (#38-43, #59)-an area FDA said it hopes to soon require mandatory, instead of optional, submission for-and new guidance on pharmaceutical compounding (#54), which FDA has at times argued it lacks sufficient regulatory authority to issue.

Also of note are guidance documents on the inclusion of pregnant women (#16) and children (#25, #53), the development of rare disease therapies (#17), the rarely used animal rule pathway (#2), the size and physical attributes of generic tablet medications (#12), the use and modification of Risk Evaluation and Mitigation Strategies (REMS) plans (#18, #48, #58), the use of multiple endpoints in clinical trials (#26), a quality systems approach to pharmaceutical current good manufacturing practices (CGMP) (#27), and ways to reduce medication errors (#33, #36, #37).

The full list, organized for your convenience, may be found below.


Advertising

1.)

Considerations for Regulatory Submissions of Promotional Labeling and Advertising Materials including Submissions in Electronic Format

Animal Rule

2.)

Product Development Under the Animal Rule

Biopharmaceuticals

3.)

Food-Effect Bioavailability and Fed Bioequivalence Studies---Bioavailability and Bioequivalence Studies for Orally Administered Drug Products Submitted in New Drug Applications General Consideration

Biosimilarity

4.)

Submission of Clinical Pharmacology Data as Evidence of Biosimilarity for Biologics and Protein Products

Chemistry

5.)

Allowable Excess Volume and Labeled Vial Fill Size

6.)

Bioequivalence Studies with Pharmacokinetic Endpoints for Drug Products Submitted in Abbreviated New Drug Applications

7.)

CMC Postapproval Manufacturing Changes Reportable in Annual Reports for Specified Biological Products

8.)

Comparability Protocols for Approved Drugs: Chemistry, Manufacturing, and Controls Information

9.)

Elemental Impurities in Drug Products Marketed in the United States

10.)

Immunogenicity Considerations for Low Molecular Weight Heparin

11.)

Liposome Drug Products: CMC, Human Pharmacokinetic and Bioavailability; and Labeling Documentation 

12.)

Size and Physical Attributes of Generic Tablets (Deleted29 July 2013)

Clinical/Antimicrobial

13.)

Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment

14.)

Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment

15.)

Antibacterial Therapies for Patients with Limited or No Alternative Therapies for the Treatment of Serious Bacterial Diseases

NEW

Pulmonary Tuberculosis: Developing Drugs for Treatment

 (Added 29 July 2013)

Clinical/Medical

16.)

Pregnant Women in Clinical Trials - Scientific and Ethical Considerations

17.)

Common Issues in Drug Development for Rare Diseases

18.)

Modifications and Revisions of Risk Evaluation and Mitigation Strategies (REMS)

19.)

Alzheimer's Disease: Developing Drugs for the Treatment of Early State Disease

20.)

Developing Drug and Biological Products for Analgesic Indications

NEW

Standards for Clinical Trial Imaging Endpoints (Added 8 March 2013)

CMC & Clinical/Medical

21.)

Immunogenicity Assessment for Therapeutic Protein Products

Clinical Pharmacology

22.)

Bioanalytical Methods Validation

23.)

Clinical Pharmacogenomics: Study Design and Premarketing Evaluation

24.)

Clinical Pharmacology Consideration for Therapeutics Proteins

25.)

General Clinical Pharmacology Considerations for Pediatrics Studies for Drugs and Biological Products

NEW

Clinical Lactation Trials - Trial Design, Data Analysis and Recommendations for Labeling (Added 8 March 2013)

NEW

Pharmacokinetics During Pregnancy and the Postpartum Period - Trial Design, Data Analysis, and Impact on Dosing and Labeling (Added 8 March 2013)

Clinical/Statistical

26.)

Multiple Endpoints in Clinical Trials

Current Good Manufacturing Practices (CGMPs)/Compliance

27.)

Quality Systems Approach to Pharmaceutical cGMP Regulation (OMPQ)

28.)

Uniformity of In-Process Mixtures (OMPQ)

29.)

Control of Highly Potent Compounds (OMPQ)

30.)

Contract Manufacturing Arrangements for Drugs: Quality Agreements

31.)

Submission of Field Alert Reports and Biological Product Deviation Reports (OMPQ)

32.)

Pre-Launch Activities Importation Request (PLAIR)

Drug Safety Information

33.)

Safety Considerations in Product Design to Minimize Medication Errors

34.)

Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages

35.)

Providing Postmarket Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report)

36.)

Safety Considerations for Container Label and Carton Labeling Design to Minimize Medication Errors

37.)

Best Practices in Developing Proprietary Names to Minimize Medication Errors

Electronic Submissions

38.)

Providing Regulatory Submissions in Electronic Format - General Considerations

39.)

Providing Regulatory Submissions in Electronic Format - Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications

40.)

Providing Regulatory Submissions in Electronic Format - Postmarketing Safety Reports

41.)

Providing Regulatory Submissions in Electronic Format - Standardized Study Data

42.)

Providing Submissions in Electronic Format - Summary Level Clinical Site Data for CDER's Inspection Planning

43.)

Providing Submissions in Electronic Format - Postmarket Non-Expedited Individual Case Safety Reports; Technical Questions and Answers

Investigational New Drugs (INDs)

44.)

Adverse Events: Collection and Reporting for Secondary Endpoints

Labeling

45.)

Drug Names and Dosage Forms

46.)

Pediatric Information:  Incorporating into Human Prescription Drug and Biological Products Labeling

Pharmacology/Toxicology

47.)

Endocrine Disruption Potential of Drugs: Non Clinical Evaluation

Procedural

48.)

Applying the Criteria for Requiring a Risk Evaluation and Mitigation Strategy (REMS)

49.)

Expedited Programs for Serious Conditions, Drugs and Biologics

50.)

Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants

51.)

Integrated Summary of Safety

52.)

Investigational New Drug Applications prepared and submitted by Clinical Sponsor Investigators

53.)

Pediatric Product Development

54.)

Pharmacy Compounding of Human Drugs Under Section 503A of the Federal Food, Drug, and Cosmetic Act

55.)

Public Disclosure of FDA-Sponsored Studies

56.)

Prescription Drug Marketing Act (PDMA) Requirements

57.)

Reporting Drug Sample Distribution Under Section 6004 of the Affordable Care Act

58.)

Use of a Master File for Shared System Risk Evaluation and Mitigation Strategies

59.)

Electronic Source Data in Clinical Investigations

NEW

Submission of Study Protocols for Drug Products with Certain Risk Evaluation and Mitigation Strategies for Review by the Office of Generic Drugs (Added 29 July 2013)


Note: This Article was originally published on 31 January 2013. It has since been updated to reflect changes in FDA's Guidance Agenda. Last update on 29 July 2013.

Share this article:

Categories: FDA, CDER

Tags: Guidance Agenda, List, pharmaceutical, draft guidance, guidance, drug

Regulatory Exchange: Latest Updates From the Community